As a new-type foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has built a "1+2+3+4=1" service system and can supply raw materials of Echinacea Purpurea Extract from multiple well-known original manufacturers.
Boasting R&D capabilities, HiSiaddi has repeatedly proposed formula optimization solutions and application improvement suggestions for Echinacea Purpurea Extract products through technological cooperation with factories and accurate insight into market needs. Below is a case of HiSiaddi’s formula optimization consulting service for Echinacea Purpurea Extract products.
Please contact HiSiaddi customer service if you require more formula optimization consulting services.
The buyer is HerbaCare A/S based in Copenhagen, Denmark, a mid-to-high-end local pharmaceutical enterprise in Northern Europe specializing in respiratory care capsules and children’s botanical oral liquids. Its products are sold in national chain pharmacies, private pediatric clinics in Denmark and high-end organic supermarkets in Sweden. Raw materials must comply with EU EC396 standard covering 226 pesticide residue items, LFGB, USP Pharmacopoeia and EU cGMP production standards.
The enterprise used to import medicinal Echinacea raw materials from Germany all year round. Affected by production reduction and price hikes in European producing areas, it launched China-based procurement with an annual total procurement volume of 13.6 tons and two mandatory customized indicators: refined capsule powder with cichoric acid ≥4.0% and total phenols ≥8.5%, no added starch or dextrin; cold-water instant modified water-soluble powder for oral liquids, free of precipitation or stratification after 90 days of refrigeration at 4°C.
After independently sourcing raw materials from three domestic plant extract manufacturers and feeding them into Denmark’s GMP production lines, multiple production and formulation compatibility failures occurred consecutively, delaying the new product launch by 75 days. Losses incurred by scrapped raw materials, production line shutdowns and third-party testing totaled 298,000 Danish Kroner. Original suppliers only produced general bulk crude powder complying with national standards and lacked capabilities for technical rectification matching formulation production. The client entrusted HiSiaddi’s technical team to conduct troubleshooting and rectification across five dimensions: raw materials, production processes, powder properties, formulas and warehousing.
Original suppliers randomly mixed standardized GAP-certified Echinacea Purpurea from Chifeng, Inner Mongolia, rapidly grown greenhouse seedlings from Hebei and low-quality wild grass from scattered farmers in Shanxi for feeding. High-quality GAP Echinacea Purpurea from Chifeng has an intrinsic cichoric acid baseline of 1.1%–1.3%, while greenhouse seedlings only contain 0.4%–0.6%. The feeding ratio was arbitrarily adjusted based on procurement costs, resulting in finished cichoric acid ranging from 2.8% to 4.4%, with most batches failing to meet the minimum 4.0% threshold; total phenol content fluctuated synchronously. The Danish pharmaceutical factory could not fix feeding conversion ratios, leading to drastic swings in active ingredient content of mass-produced capsules, with multiple finished batches seized by the Danish Food and Drug Administration during sampling inspections. Raw materials from scattered farmers were treated with pesticides without standardized management, with heavy metal and pesticide residue indicators approaching EU limit thresholds.
Cichoric acid undergoes oxidative hydrolysis at temperatures above 65°C. Manufacturers adopted long-term high-temperature ethanol reflux extraction at 78–85°C, causing over 31% degradation loss of cichoric acid. Even with full feeding of high-quality Chifeng raw materials, stable compliance with core indicators was hard to achieve. Open extraction equipment lacked closed solvent recovery devices, leading to ethanol residues generally exceeding 6100ppm in finished products, far above the client’s internal control standard of ≤2800ppm. After soft capsule filling, gelatin shells were infiltrated and softened by solvents, resulting in a product scrap rate as high as 27.2%.
All raw materials were uniformly processed into crude powder via spray drying without targeted powder modification for capsule and oral liquid production lines.
· Capsule workshop: Widely varying powder particle sizes and high fine powder proportion, repose angle >47°, electrostatic agglomeration and silo bridging, requiring production line shutdown and cleaning every 50 minutes on average, with maximum single capsule weight deviation of 7.9%, exceeding the ±2% control range specified in Danish Pharmacopoeia;
· Oral liquid workshop: Poor water solubility of Echinacea polyphenols without inclusion modification of crude powder, turbid liquid after cold water mixing, brown flocculent precipitates separating out after 7 days of low-temperature storage, destroying the colloidal system of oral liquids and disqualifying finished products for retention testing.
The mature Danish formula blended Echinacea Purpurea Extract with citric acid and compound vitamin C for oral liquid preparation. Crude extracts retained large amounts of native gum, crude fiber and trace heavy metal impurities. Metal ions catalyzed the oxidation of vitamin C, turning the liquid from light yellow to dark brown after 45 days at room temperature, with active ingredient loss exceeding 15%, failing to meet the EU mandatory 24-month shelf life standard. The pharmaceutical factory only slightly delayed discoloration after three rounds of vitamin C raw material replacement and excipient ratio adjustment, unable to eliminate the root cause from the raw material end.
Conventional spray drying by manufacturers resulted in finished product moisture >1.4%. Denmark’s annual warehouse humidity averages around 52%, causing raw materials to absorb moisture and cake within 2–3 days after unpacking, blocking screening meshes and adhering to capsule pressing molds during feeding. The pharmaceutical factory added manual crushing procedures, continuously driving up production costs and defective product rates.
HiSiaddi set up a team consisting of plant extract engineers, dietary formula consultants and physical & chemical testing specialists, conducting on-site docking with Chifeng GAP planting bases and compliant refining factories. Rectification was implemented in five phases: targeted raw material control → extraction process upgrade → multi-stage resin deep purification → differentiated powder modification by dosage form → collaborative formula optimization + standardized warehousing guidance, with repeated sample verification across three stages: laboratory small samples, 70kg pilot trials and large-scale mass production.
HiSiaddi conducted field visits to Harqin Banner, Chifeng, Inner Mongolia, and signed annual exclusive harvesting agreements with 3 certified standardized Echinacea Purpurea planting cooperatives. Whole plants were centrally mechanically harvested after full flowering in autumn, with diseased plants, greenhouse seedlings and moldy raw materials manually sorted out. Raw materials were pre-tested for intrinsic cichoric acid content upon incoming inspection, and entire batches with baseline below 1.0% were rejected to completely eliminate mixed feeding of inferior miscellaneous raw materials.
The high-temperature reflux extraction process was fully eliminated, replaced by 42°C low-temperature segmented percolation + gradient ethanol extraction + negative pressure low-temperature concentration + tandem refining with AB8 and D101 resins, with fully closed and light-shielded production. Cichoric acid degradation rate was controlled within 5.5%. Resins removed gum and crude fiber impurities, resulting in finished cichoric acid stably ranging from 4.03% to 4.09% and total phenols from 8.6% to 8.9%. A three-stage closed distillation recovery device was equipped to control ethanol residues within 2700ppm, completely resolving the capsule shell leakage issue.
1. Refined medicinal powder for capsules: Low-temperature vacuum drying paired with nitrogen-protected air flow ultrafine grinding, optimized powder repose angle 33°±2°, uniform particles with excellent fluidity, no additional anti-caking excipients, compatible with high-speed automatic capsule filling;
2. Cold-water instant powder for oral liquids: Starch/dextrin-free β-cyclodextrin inclusion modification under low-temperature conditions, drastically improving water solubility of polyphenols after modification for instant complete dissolution in cold water, clear solution without precipitation or stratification after 90 days of constant-temperature storage at 4°C.
At the raw material end, multi-stage resins removed heavy metals and oxidation-promoting macromolecular impurities. At the formulation end, HiSiaddi remotely coordinated with the Danish R&D team to optimize feeding logic: separate pre-mixing and staged feeding of Echinacea raw materials, organic acids and vitamins to avoid direct contact between metal ions and vitamin C triggering catalytic oxidation. 90-day accelerated stability samples showed no browning or discoloration, successfully passing EU shelf-life testing.
Finished products adopted segmented vacuum low-temperature dehydration processes, stabilizing moisture of all batches ≤0.5%. HiSiaddi compiled bilingual (Danish + English) warehouse operation specifications, requiring the client to maintain constant warehouse temperature at 22°C and environmental humidity ≤40%. Raw materials were packed in vacuum nitrogen-filled aluminum foil small bags for unpacking and feeding on demand, completely eliminating raw material caking issues in high-humidity environments.
After 4 rounds of cross-border sample delivery, full-item pesticide residue and physical & chemical testing by authoritative third-party laboratories in Denmark, plus 30 consecutive days of uninterrupted pilot production at the client’s GMP workshop, both customized raw material varieties passed pre-entry review by the Danish Drug Administration. The first batch of 4.7 tons of finished products was shipped from Shanghai Port to Copenhagen, clearing customs in one inspection upon arrival. After production launch, capsule weight deviation was stably controlled within ±1.7%, and the product scrap rate dropped from 27.2% to 1.02%. All batches of oral liquid showed no precipitation during low-temperature retention testing, and the new product whose launch had been delayed by 75 days successfully completed Danish product filing for full-channel distribution in high-end pharmacies and pediatric clinics.
HerbaCare of Denmark signed a long-term procurement framework for an annual volume of 13.6 tons: 7.8 tons of capsule refined powder and 5.8 tons of oral liquid water-soluble powder, split into 11 monthly production batches throughout the year. The client added customized low-impurity Echinacea for infant drops the following year, with HiSiaddi fully overseeing full-process process debugging, sample testing and technical optimization. Compared with German imported raw materials, comprehensive domestic procurement costs decreased by 30.3%, and sea freight lead time was shortened from 74 days to 20 days. Backed by this benchmark Northern European client, cooperative domestic factories subsequently secured annual raw material orders from two equivalent pharmaceutical enterprises in Finland and Norway.
Most small and medium-sized domestic plant extract enterprises focus on low-cost crude bulk processing, lacking targeted raw material control and outdated fixed production processes. They lack R&D capabilities for powder modification and formulation supporting development, and conduct insufficient professional research on the thermosensitive characteristics of cichoric acid and terminal production conditions in European and American markets. Mid-to-high-end Danish pharmaceutical enterprises devote intensive efforts to formulation and terminal preparation, well-versed in strict local drug regulatory standards, yet unfamiliar with quality stratification of domestic Echinacea producing areas and uneven factory process capabilities. Blind independent procurement often leads to mass production failures, delayed new product launches and substantial economic losses.
Relying on upstream origin resources and composite technical reserves covering plant extraction and formulation preparation, HiSiaddi forms a closed-loop full-industrial-chain technical service system from raw material sources to terminal production, bridging Chinese and foreign technological information gaps and helping high-end domestic Echinacea Purpurea Extract smoothly enter Northern European supply chains for pharmaceutical-grade high-end raw materials.
Please contact HiSiaddi customer service if you require more formula optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
